Filing Flows › Comparisons › ADPT vs BDTX
Adaptive Biotechnologies vs Black Diamond Therapeutics: ADPT and BDTX compared
Adaptive Biotechnologies is the larger company: $83.9M of revenue in its latest quarter (Q3 2026) against $70.0M for Black Diamond Therapeutics (Q1 2025). Black Diamond Therapeutics is more profitable, with an operating margin of 77.9% against -0.5%.
Where the money goes: ADPT and BDTX
Adaptive Biotechnologies (ADPT) · Q3 2026
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
Black Diamond Therapeutics (BDTX) · Q1 2025
Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.
| Adaptive Biotechnologies (ADPT) | Black Diamond Therapeutics (BDTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2025 |
| Revenue | $83.9M | $70.0M |
| Revenue growth, Y/Y | -11% | — |
| Operating margin | -0.5% | 77.9% |
| Net earnings | $2.8M | $56.5M |
| Net margin | 3.3% | 80.8% |
| Operating cash flow | $9.6M | $53.4M |
| Free cash flow | $7.7M | — |
Questions
Which is bigger, Adaptive Biotechnologies or Black Diamond Therapeutics?
Adaptive Biotechnologies is the larger company: $83.9M of revenue in its latest quarter (Q3 2026) against $70.0M for Black Diamond Therapeutics (Q1 2025).
Is Adaptive Biotechnologies or Black Diamond Therapeutics growing faster?
Black Diamond Therapeutics is more profitable, with an operating margin of 77.9% against -0.5%.
More: Adaptive Biotechnologies earnings · how Adaptive Biotechnologies makes money · Black Diamond Therapeutics earnings · how Black Diamond Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed May 12, 2025). Fiscal quarters can end on different dates. Not investment advice.